Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1987 Apr;31(4):505–511. doi: 10.1128/aac.31.4.505

In vitro activity and beta-lactamase stability of a new monobactam, B0-1165.

H C Neu, N X Chin
PMCID: PMC174767  PMID: 3300528

Abstract

B0-1165 is a 1-carboxy-1-cyclopropoxyamino,4-fluoromethyl monobactam. It inhibited the majority of Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Citrobacter diversus, Aeromonas hydrophila, Proteus mirabilis, Proteus vulgaris, Providencia rettgeri, Providencia stuartii, Yersinia enterocolitica, Haemophilus influenzae, Neisseria gonorrhoeae, and Salmonella and Shigella species at less than or equal to 0.125 microgram/ml. Overall, its in vitro activity was similar to that of aztreonam, cefotaxime, and ceftazidime, with minor differences in the MICs for individual isolates. Enterobacter species and Citrobacter freundii which were derepressed for beta-lactamase production and had higher MICs of aztreonam and ceftazidime had MICs that ranged from 4 to 32 micrograms/ml. B0-1165 had activity against Pseudomonas aeruginosa similar to that of aztreonam but lower than that of ceftazidime and carumonam. Pseudomonas maltophilia and other Pseudomonas species were resistant or had MICs of 32 micrograms/ml, as did Acinetobacter species. B0-1165 did not inhibit streptococcal, staphylococcal, or anaerobic species, such as Clostridium and Bacteroides species. B0-1165 was not hydrolyzed to any appreciable extent by common plasmid- and chromosomally Richmond-Sykes type 1a-, 1c-, and 1d-mediated beta-lactamases. It inhibited the Enterobacter cloacae P99 and inducible Pseudomonas aeruginosa beta-lactamases. B0-1165 was a poor inducer of beta-lactamase, but exposing E. cloacae and C. freundii to B0-1165 selected for resistant isolates. Overall, B0-1165 had in vitro properties similar to those of other monobactams currently available or under investigation.

Full text

PDF
505

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Imada A., Kondo M., Okonogi K., Yukishige K., Kuno M. In vitro and in vivo antibacterial activities of carumonam (AMA-1080), a new N-sulfonated monocyclic beta-lactam antibiotic. Antimicrob Agents Chemother. 1985 May;27(5):821–827. doi: 10.1128/aac.27.5.821. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Mandell W., Neu H. C. Antimicrobial activity and beta-lactamase stability of foramidocillin. Antimicrob Agents Chemother. 1986 May;29(5):769–773. doi: 10.1128/aac.29.5.769. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Matsuda K., Nagashima M., Nakagawa S., Inoue M., Mitsuhashi S. In-vitro antibacterial activity of BO-1165, a new monobactam antibiotic. J Antimicrob Chemother. 1986 Jun;17(6):747–753. doi: 10.1093/jac/17.6.747. [DOI] [PubMed] [Google Scholar]
  4. Neu H. C., Chin N. X., Labthavikul P. The in-vitro activity and beta-lactamase stability of carumonam. J Antimicrob Chemother. 1986 Jul;18(1):35–44. doi: 10.1093/jac/18.1.35. [DOI] [PubMed] [Google Scholar]
  5. Neu H. C., Labthavikul P. In vitro activity and beta-lactamase stability of a monobactam, SQ 26,917, compared with those of aztreonam and other agents. Antimicrob Agents Chemother. 1983 Aug;24(2):227–232. doi: 10.1128/aac.24.2.227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Pearson R. D., Steigbigel R. T., Davis H. T., Chapman S. W. Method of reliable determination of minimal lethal antibiotic concentrations. Antimicrob Agents Chemother. 1980 Nov;18(5):699–708. doi: 10.1128/aac.18.5.699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Sanders C. C., Sanders W. E., Jr Emergence of resistance during therapy with the newer beta-lactam antibiotics: role of inducible beta-lactamases and implications for the future. Rev Infect Dis. 1983 Jul-Aug;5(4):639–648. doi: 10.1093/clinids/5.4.639. [DOI] [PubMed] [Google Scholar]
  8. Scully B. E., Neu H. C. Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa. Am J Med. 1985 Feb;78(2):251–261. doi: 10.1016/0002-9343(85)90435-8. [DOI] [PubMed] [Google Scholar]
  9. Skotnicki J. S., Commons T. J., Rees R. W., Speth J. L. Synthesis and biological evaluation of a 4-fluoromethyl monobactam analog. J Antibiot (Tokyo) 1983 Sep;36(9):1201–1204. doi: 10.7164/antibiotics.36.1201. [DOI] [PubMed] [Google Scholar]
  10. Sykes R. B., Bonner D. P., Bush K., Georgopapadakou N. H. Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria. Antimicrob Agents Chemother. 1982 Jan;21(1):85–92. doi: 10.1128/aac.21.1.85. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Vu H., Nikaido H. Role of beta-lactam hydrolysis in the mechanism of resistance of a beta-lactamase-constitutive Enterobacter cloacae strain to expanded-spectrum beta-lactams. Antimicrob Agents Chemother. 1985 Mar;27(3):393–398. doi: 10.1128/aac.27.3.393. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. White A. J., Curtis N. A. Hydrolysis of beta-lactamase-stable beta-lactams by type I 'sponge' beta-lactamases. J Antimicrob Chemother. 1985 Sep;16(3):403–405. doi: 10.1093/jac/16.3.403. [DOI] [PubMed] [Google Scholar]
  13. Williams J. F., el Khalifa M., Mackenzie C. D., Sisley B. Antigens of Onchocerca volvulus. Rev Infect Dis. 1985 Nov-Dec;7(6):831–836. doi: 10.1093/clinids/7.6.831. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES